Phase III Aspire Study Misses Both Efficacy Endpoints in Angelman Syndrome
Ultragenyx said the Phase III Aspire trial of intrathecal apazunersen in Angelman syndrome missed its primary Bayley-4 cognition endpoint and key secondary Multidomain Responder Index endpoint. The company found no treated-versus-control difference supportive of…
